Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,495928,plasma concentration,"The mean effective dTC plasma concentration for 50% paralysis during the infusion (onset) was 0.93 micrograms/ml, but was lower post-infusion (offset) (0.54 micrograms/ml, p less than 0.001).",Studies in man with a constant-rate infusion of tubocurarine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495928/),[μg] / [ml],0.93,19733,DB01199,Tubocurarine
,495928,plasma concentration,"The mean effective dTC plasma concentration for 50% paralysis during the infusion (onset) was 0.93 micrograms/ml, but was lower post-infusion (offset) (0.54 micrograms/ml, p less than 0.001).",Studies in man with a constant-rate infusion of tubocurarine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495928/),[μg] / [ml],0.54,19734,DB01199,Tubocurarine
,495928,steady state dTC plasma concentration,The steady state dTC plasma concentration which should produce 95% paralysis was predicted to lie between 0.95 and 1.67 micrograms/ml.,Studies in man with a constant-rate infusion of tubocurarine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495928/),[μg] / [ml],0.95 and 1.67,19735,DB01199,Tubocurarine
,495928,ED50,"The results were pooled for all patients at a stimulation rate of 0.1 Hz, giving a mean effective dose of dTC at 95% paralysis of 0.53 mg/kg, and an ED50 of 0.22 mg/kg.",Studies in man with a constant-rate infusion of tubocurarine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495928/),[mg] / [kg],0.22,19736,DB01199,Tubocurarine
,3315392,volumes of distribution at steady state,"The kinetic parameters including volumes of distribution at steady state of 0.35 L/kg and 0.34 L/kg and elimination clearances of 1.3 ml/min/kg and 1.1 ml/min/kg in the control and CPB groups, respectively, are in agreement with the results of others.",Metocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315392/),[l] / [kg],0.35,25689,DB01199,Tubocurarine
,3315392,volumes of distribution at steady state,"The kinetic parameters including volumes of distribution at steady state of 0.35 L/kg and 0.34 L/kg and elimination clearances of 1.3 ml/min/kg and 1.1 ml/min/kg in the control and CPB groups, respectively, are in agreement with the results of others.",Metocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315392/),[l] / [kg],0.34,25690,DB01199,Tubocurarine
,3315392,elimination clearances,"The kinetic parameters including volumes of distribution at steady state of 0.35 L/kg and 0.34 L/kg and elimination clearances of 1.3 ml/min/kg and 1.1 ml/min/kg in the control and CPB groups, respectively, are in agreement with the results of others.",Metocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315392/),[ml] / [kg·min],1.3,25691,DB01199,Tubocurarine
,3315392,elimination clearances,"The kinetic parameters including volumes of distribution at steady state of 0.35 L/kg and 0.34 L/kg and elimination clearances of 1.3 ml/min/kg and 1.1 ml/min/kg in the control and CPB groups, respectively, are in agreement with the results of others.",Metocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315392/),[ml] / [kg·min],1.1,25692,DB01199,Tubocurarine
,3161430,total duration of,"Similarly, the total duration of neuromuscular blockade, measured to recovery to 90% of control ECEMG, was significantly shorter in the phenytoin group (122 +/- 25 min compared with 269 +/- 64 min in the control group, P less than 0.01).",Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161430/),min,122,46564,DB01199,Tubocurarine
,3161430,total duration of,"Similarly, the total duration of neuromuscular blockade, measured to recovery to 90% of control ECEMG, was significantly shorter in the phenytoin group (122 +/- 25 min compared with 269 +/- 64 min in the control group, P less than 0.01).",Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161430/),min,269,46565,DB01199,Tubocurarine
,10360874,effect compartment concentration,"The metocurine effect compartment concentration associated with a 50% diminution of twitch height after 3 weeks was 1,716+/-1,208 ng/ml (mean +/- SD), which was significantly different from 257+/-34 ng/ml, the value on day 0.",Deep sedation and mechanical ventilation without paralysis for 3 weeks in normal beagles: exaggerated resistance to metocurine in gastrocnemius muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360874/),[ng] / [ml],"1,716",48194,DB01199,Tubocurarine
,10360874,effect compartment concentration,"The metocurine effect compartment concentration associated with a 50% diminution of twitch height after 3 weeks was 1,716+/-1,208 ng/ml (mean +/- SD), which was significantly different from 257+/-34 ng/ml, the value on day 0.",Deep sedation and mechanical ventilation without paralysis for 3 weeks in normal beagles: exaggerated resistance to metocurine in gastrocnemius muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360874/),[ng] / [ml],257,48195,DB01199,Tubocurarine
,7199837,unbound central volume of distribution,"The unbound central volume of distribution and renal excretion at 24 hours were significantly increased in burned patients (0.11 +/- 0.03 L/kg vs 0.057 +/- 0.015 L/kg, p less than 0.05, 57% +/- 7% vs 40% +/- 11%, p less than 0.05, respectively).",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),[l] / [kg],0.11,55204,DB01199,Tubocurarine
,7199837,renal excretion,"The unbound central volume of distribution and renal excretion at 24 hours were significantly increased in burned patients (0.11 +/- 0.03 L/kg vs 0.057 +/- 0.015 L/kg, p less than 0.05, 57% +/- 7% vs 40% +/- 11%, p less than 0.05, respectively).",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),%,57,55205,DB01199,Tubocurarine
,7199837,renal excretion,"The unbound central volume of distribution and renal excretion at 24 hours were significantly increased in burned patients (0.11 +/- 0.03 L/kg vs 0.057 +/- 0.015 L/kg, p less than 0.05, 57% +/- 7% vs 40% +/- 11%, p less than 0.05, respectively).",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),%,40,55206,DB01199,Tubocurarine
,7199837,elimination half-lives,"On the other hand, comparable elimination half-lives (6.5 +/- 1.8 hr vs 6.2 +/- 1.3 hr, p greater than 0.05), unbound volume of distribution (0.86 +/- 0.2 L/kg vs 0.96 +/- 0.5 L/kg, p greater than 0.05), and intrinsic clearances (1.62 +/- 0.6 ml/kg/min vs 1.56 +/- 0.4 ml/kg/min, p greater than 0.05) were present in burned patients and control patients, respectively.",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),h,6.5,55207,DB01199,Tubocurarine
,7199837,elimination half-lives,"On the other hand, comparable elimination half-lives (6.5 +/- 1.8 hr vs 6.2 +/- 1.3 hr, p greater than 0.05), unbound volume of distribution (0.86 +/- 0.2 L/kg vs 0.96 +/- 0.5 L/kg, p greater than 0.05), and intrinsic clearances (1.62 +/- 0.6 ml/kg/min vs 1.56 +/- 0.4 ml/kg/min, p greater than 0.05) were present in burned patients and control patients, respectively.",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),h,6.2,55208,DB01199,Tubocurarine
,7199837,unbound volume of distribution,"On the other hand, comparable elimination half-lives (6.5 +/- 1.8 hr vs 6.2 +/- 1.3 hr, p greater than 0.05), unbound volume of distribution (0.86 +/- 0.2 L/kg vs 0.96 +/- 0.5 L/kg, p greater than 0.05), and intrinsic clearances (1.62 +/- 0.6 ml/kg/min vs 1.56 +/- 0.4 ml/kg/min, p greater than 0.05) were present in burned patients and control patients, respectively.",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),[l] / [kg],0.86,55209,DB01199,Tubocurarine
,7199837,unbound volume of distribution,"On the other hand, comparable elimination half-lives (6.5 +/- 1.8 hr vs 6.2 +/- 1.3 hr, p greater than 0.05), unbound volume of distribution (0.86 +/- 0.2 L/kg vs 0.96 +/- 0.5 L/kg, p greater than 0.05), and intrinsic clearances (1.62 +/- 0.6 ml/kg/min vs 1.56 +/- 0.4 ml/kg/min, p greater than 0.05) were present in burned patients and control patients, respectively.",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),[l] / [kg],0.96,55210,DB01199,Tubocurarine
,7199837,intrinsic clearances,"On the other hand, comparable elimination half-lives (6.5 +/- 1.8 hr vs 6.2 +/- 1.3 hr, p greater than 0.05), unbound volume of distribution (0.86 +/- 0.2 L/kg vs 0.96 +/- 0.5 L/kg, p greater than 0.05), and intrinsic clearances (1.62 +/- 0.6 ml/kg/min vs 1.56 +/- 0.4 ml/kg/min, p greater than 0.05) were present in burned patients and control patients, respectively.",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),[ml] / [kg·min],1.62,55211,DB01199,Tubocurarine
,7199837,intrinsic clearances,"On the other hand, comparable elimination half-lives (6.5 +/- 1.8 hr vs 6.2 +/- 1.3 hr, p greater than 0.05), unbound volume of distribution (0.86 +/- 0.2 L/kg vs 0.96 +/- 0.5 L/kg, p greater than 0.05), and intrinsic clearances (1.62 +/- 0.6 ml/kg/min vs 1.56 +/- 0.4 ml/kg/min, p greater than 0.05) were present in burned patients and control patients, respectively.",Pharmacokinetics of d-tubocurarine in patients with thermal injury. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199837/),[ml] / [kg·min],1.56,55212,DB01199,Tubocurarine
,8789701,IC50,Isoflurane increased the potency of metocurine significantly; IC50 (the concentration in the effect compartment at 50% paralysis) was 70 +/- 15 ng/mL during isoflurane anaesthesia and 129 +/- 42 ng/mL during barbiturate-opiate anaesthesia (P < 0.03).,Metocurine pharmacokinetics and pharmacodynamics in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ng] / [ml],70,75095,DB01199,Tubocurarine
,8789701,IC50,Isoflurane increased the potency of metocurine significantly; IC50 (the concentration in the effect compartment at 50% paralysis) was 70 +/- 15 ng/mL during isoflurane anaesthesia and 129 +/- 42 ng/mL during barbiturate-opiate anaesthesia (P < 0.03).,Metocurine pharmacokinetics and pharmacodynamics in goats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ng] / [ml],129,75096,DB01199,Tubocurarine
,8789701,Volume of distribution,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ml] / [kg],63,75097,DB01199,Tubocurarine
,8789701,clearance,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ml] / [kg·min],1.6,75098,DB01199,Tubocurarine
,8789701,clearance,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),[ml] / [kg],64,75099,DB01199,Tubocurarine
,8789701,elimination half-life,"Volume of distribution (63 +/- 18 mL/kg), clearance (1.6 +/- 0.4 mL/min.kg) and elimination half-life (99 +/- 9 min) during barbiturate-opiate anaesthesia were not significantly different during isoflurane anaesthesia: 64 +/- 25 mL/kg, 1.5 +/- 0.7 mL/kg.min, 116 +/- 16 min respectively.",Metocurine pharmacokinetics and pharmacodynamics in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789701/),min,99,75100,DB01199,Tubocurarine
less,216382,disposition (distribution) half-life,The fast disposition (distribution) half-life of the drug was invariably less than 1 min; the slow disposition (elimination) half-life ranged from 15.4--31.7 min.,Pharmacokinetics and pharmacological effects of neostigmine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216382/),min,1,80568,DB01199,Tubocurarine
,216382,disposition (elimination) half-life,The fast disposition (distribution) half-life of the drug was invariably less than 1 min; the slow disposition (elimination) half-life ranged from 15.4--31.7 min.,Pharmacokinetics and pharmacological effects of neostigmine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/216382/),min,15.4--31.7,80569,DB01199,Tubocurarine
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.74,97583,DB01199,Tubocurarine
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.52,97584,DB01199,Tubocurarine
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.41,97585,DB01199,Tubocurarine
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.30,97586,DB01199,Tubocurarine
,7114542,elimination half-life (t beta 1/2),"The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),min,174,97587,DB01199,Tubocurarine
,7114542,elimination half-life (t beta 1/2),"The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),min,90,97588,DB01199,Tubocurarine
,7114542,elimination half-life (t beta 1/2),"The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),min,89,97589,DB01199,Tubocurarine
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],6.7,107246,DB01199,Tubocurarine
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],9.5,107247,DB01199,Tubocurarine
,736287,ED50,The serum concentration of dTc necessary for neuromuscular blockade was less at 39 C (ED50 0.87 microgram/ml) than at 34 or 28 C (ED50 1.13 microgram/ml).,Pharmacokinetics and pharmacodynamics of d-tubocurarine during hypothermia in the cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/736287/),[μg] / [ml],0.87,128400,DB01199,Tubocurarine
,736287,ED50,The serum concentration of dTc necessary for neuromuscular blockade was less at 39 C (ED50 0.87 microgram/ml) than at 34 or 28 C (ED50 1.13 microgram/ml).,Pharmacokinetics and pharmacodynamics of d-tubocurarine during hypothermia in the cat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/736287/),[μg] / [ml],1.13,128401,DB01199,Tubocurarine
,2719307,time to recover to 50% of maximal twitch depression,"The time course of effect was also similar, although the maximum twitch depression was significantly smaller (66.1% vs. 100% maximal twitch depression) and time to recover to 50% of maximal twitch depression was significantly shorter (14.2 vs. 52 min) in thermally injured patients.",Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719307/),min,14.2,131508,DB01199,Tubocurarine
,2719307,time to recover to 50% of maximal twitch depression,"The time course of effect was also similar, although the maximum twitch depression was significantly smaller (66.1% vs. 100% maximal twitch depression) and time to recover to 50% of maximal twitch depression was significantly shorter (14.2 vs. 52 min) in thermally injured patients.",Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719307/),min,52,131509,DB01199,Tubocurarine
,665974,half-lives,The mean half-lives for the two phases in the human studies were 8.9 and 123.8 minuts.,Studies of d-tubocurarine pharmacokinetics in humans and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/665974/),minuts,8.9,140185,DB01199,Tubocurarine
,665974,half-lives,The mean half-lives for the two phases in the human studies were 8.9 and 123.8 minuts.,Studies of d-tubocurarine pharmacokinetics in humans and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/665974/),minuts,123.8,140186,DB01199,Tubocurarine
,1687880,low detection limit,The low detection limit of this method in the patient was 3 ng/mL.,Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687880/),[ng] / [ml],3,142308,DB01199,Tubocurarine
,6767421,volume of distribution (Vdarea),"Using the four-exponential equation (data to 96 hours), the calculated volume of distribution (Vdarea) was 3.4 1/kg.",Pharmacokinetics of d-tubocurarine in man: effect of an osmotic diuretic on urinary excretion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6767421/),[1] / [kg],3.4,142370,DB01199,Tubocurarine
less,7224209,rate of increase in twitch tension,Twitch tension rapidly increased to a plateau (a rate of increase in twitch tension of less than 2 per cent of control per min) which was sustained in all cases.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),%,2,142422,DB01199,Tubocurarine
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,2.9,142423,DB01199,Tubocurarine
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,6.1,142424,DB01199,Tubocurarine
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,110,142425,DB01199,Tubocurarine
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,77,142426,DB01199,Tubocurarine
,7437228,"""","In nine of the patients the duration of infusion was sufficient to achieve a ""steady-state"" dtc concentration in the plasma (mean 1.09 microgram ml-1).",Pharmacokinetics of tubocurarine administered by combined i.v. bolus and infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437228/),[μg] / [ml],1.09,146155,DB01199,Tubocurarine
,7437228,"steady-state"" dtc concentration","In nine of the patients the duration of infusion was sufficient to achieve a ""steady-state"" dtc concentration in the plasma (mean 1.09 microgram ml-1).",Pharmacokinetics of tubocurarine administered by combined i.v. bolus and infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437228/),[μg] / [ml],1.09,146156,DB01199,Tubocurarine
,7437228,plasma concentrations,"All plasma concentrations decreased rapidly after infusion, from a mean of 1.35 microgram ml-1, in either a mono- or bi-exponential manner.",Pharmacokinetics of tubocurarine administered by combined i.v. bolus and infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437228/),[μg] / [ml],1.35,146157,DB01199,Tubocurarine
,761446,rate constant,"In 7 normal subjects, the (mean +/- SD) rate constant for equilibration of dTC effect (paralysis) and Cp is 0.13 +/- 0.04 min-1 and the (mean +/- SD) steady-state Cp required to produce 50% paralysis is 0.37 +/- 0.05 microgram/ml.",Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761446/),1/[min],0.13,155470,DB01199,Tubocurarine
,761446,steady-state Cp,"In 7 normal subjects, the (mean +/- SD) rate constant for equilibration of dTC effect (paralysis) and Cp is 0.13 +/- 0.04 min-1 and the (mean +/- SD) steady-state Cp required to produce 50% paralysis is 0.37 +/- 0.05 microgram/ml.",Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761446/),[μg] / [ml],0.37,155471,DB01199,Tubocurarine
,496054,terminal half-lives,"Plasma disappearances of both drugs were triexponential, with mean terminal half-lives of 346 and 217 min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),min,346,165691,DB01199,Tubocurarine
,496054,terminal half-lives,"Plasma disappearances of both drugs were triexponential, with mean terminal half-lives of 346 and 217 min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),min,217,165692,DB01199,Tubocurarine
,496054,Renal excretions,Renal excretions 48 hours after injection ranged from 46 to 95 per cent of the dose for d-tubocurarine and from 46 to 58 per cent for metocurine.,Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,46 to 95,165693,DB01199,Tubocurarine
,496054,Renal excretions,Renal excretions 48 hours after injection ranged from 46 to 95 per cent of the dose for d-tubocurarine and from 46 to 58 per cent for metocurine.,Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,46 to 58,165694,DB01199,Tubocurarine
,496054,total-body clearances,"Mean total-body clearances were 56 and 96 ml/min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),[ml] / [min],56,165695,DB01199,Tubocurarine
,496054,total-body clearances,"Mean total-body clearances were 56 and 96 ml/min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),[ml] / [min],96,165696,DB01199,Tubocurarine
,496054,Biliary elimination,"Biliary elimination of d-tubocurarine was greater than that of metocurine: within 48 hours 11.8 and 2.1 per cent of the doses were excreted in bile, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,11.8,165697,DB01199,Tubocurarine
,496054,Biliary elimination,"Biliary elimination of d-tubocurarine was greater than that of metocurine: within 48 hours 11.8 and 2.1 per cent of the doses were excreted in bile, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,2.1,165698,DB01199,Tubocurarine
,7023284,plasma clearance,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[ml] / [kg·min],0.38,172247,DB01199,Tubocurarine
,7023284,plasma clearance,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[ml] / [kg·min],1.2,172248,DB01199,Tubocurarine
,7023284,elimination half-life,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),h,11.4,172249,DB01199,Tubocurarine
,7023284,elimination half-life,"In the patients for renal transplant, plasma clearance of metocurine was significantly reduced (0.38 vs. 1.2 ml . kg-1 . min-1, P less than 0.01) and the elimination half-life was significantly prolonged (11.4 vs. 6.0 h, P less than 0.01).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),h,6.0,172250,DB01199,Tubocurarine
,7023284,total volume of distribution,"The higher serum concentration of metocurine in patients for renal transplant was accounted for by the absence of renal excretion and a reduced total volume of distribution (0.353 vs. 0.472 l/kg, P less than 0.05).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[l] / [kg],0.353,172251,DB01199,Tubocurarine
,7023284,total volume of distribution,"The higher serum concentration of metocurine in patients for renal transplant was accounted for by the absence of renal excretion and a reduced total volume of distribution (0.353 vs. 0.472 l/kg, P less than 0.05).",Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7023284/),[l] / [kg],0.472,172252,DB01199,Tubocurarine
,6821619,initial half-life,"In the eight patients studied, the initial half-life was 1.0 +/- 0.3 min and the terminal half-life was 46.4 +/- 6.5 min (mean +/- SEM).",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),min,1.0,173568,DB01199,Tubocurarine
,6821619,terminal half-life,"In the eight patients studied, the initial half-life was 1.0 +/- 0.3 min and the terminal half-life was 46.4 +/- 6.5 min (mean +/- SEM).",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),min,46.4,173569,DB01199,Tubocurarine
,6821619,Total body clearance,"Total body clearance of pyridostigmine was 8.7 +/- 1.5 ml min-1 kg-1, and the total apparent volume of distribution was 536 +/- 80 ml kg-1.",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),[ml] / [kg·min],8.7,173570,DB01199,Tubocurarine
,6821619,total apparent volume of distribution,"Total body clearance of pyridostigmine was 8.7 +/- 1.5 ml min-1 kg-1, and the total apparent volume of distribution was 536 +/- 80 ml kg-1.",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),[ml] / [kg],536,173571,DB01199,Tubocurarine
,6486504,ED50,The reported values for ED50 for edrophonium (obtained under similar anesthetic conditions) is 128 micrograms/kg for adults.,Clinical pharmacology of edrophonium in infants and children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[μg] / [kg],128,176742,DB01199,Tubocurarine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],17.8,176743,DB01199,Tubocurarine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],14.2,176744,DB01199,Tubocurarine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],8.3,176745,DB01199,Tubocurarine
,6145374,clearance,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],6.4,178725,DB01199,Tubocurarine
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,36,178726,DB01199,Tubocurarine
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],3.0,178727,DB01199,Tubocurarine
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,72,178728,DB01199,Tubocurarine
,195035,Terminal half lives,Terminal half lives of d-TC of 231 and 330 minutes predicted from other studies for patients with and without renal function were consistent with plasma concentrations measured.,The pharmacokinetics of d-tubocurarine in man with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/195035/),min,231,193110,DB01199,Tubocurarine
,195035,Terminal half lives,Terminal half lives of d-TC of 231 and 330 minutes predicted from other studies for patients with and without renal function were consistent with plasma concentrations measured.,The pharmacokinetics of d-tubocurarine in man with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/195035/),min,330,193111,DB01199,Tubocurarine
,3970367,Renal clearance,Renal clearance of dTc was 0.63 +/- 0.23 ml X min-1 X kg-1 and was correlated with creatinine clearance.,The pharmacokinetics of d-tubocurarine with surgery involving salvaged autologous blood. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3970367/),[ml] / [kg·min],0.63,198642,DB01199,Tubocurarine
,3970367,Total plasma clearance,"Total plasma clearance of 1.21 +/- 0.40 ml X min X -1 X kg-1 was lower than that found in many previous studies, and the predetermined continuous dTc infusion produced an apparent plateau in plasma concentrations of 1.8 +/- 0.3 micrograms X ml-1.",The pharmacokinetics of d-tubocurarine with surgery involving salvaged autologous blood. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3970367/),[-1·min·ml] / [kg],1.21,198643,DB01199,Tubocurarine
,3970367,apparent plateau in plasma concentrations,"Total plasma clearance of 1.21 +/- 0.40 ml X min X -1 X kg-1 was lower than that found in many previous studies, and the predetermined continuous dTc infusion produced an apparent plateau in plasma concentrations of 1.8 +/- 0.3 micrograms X ml-1.",The pharmacokinetics of d-tubocurarine with surgery involving salvaged autologous blood. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3970367/),[μg] / [ml],1.8,198644,DB01199,Tubocurarine
,6108730,plasma clearances,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[ml] / [min],221,212973,DB01199,Tubocurarine
,6108730,plasma clearances,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[ml] / [min],185,212974,DB01199,Tubocurarine
,6108730,terminal half-lives,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),min,30,212975,DB01199,Tubocurarine
,6108730,terminal half-lives,"Pharmacokinetic analysis demonstrated high plasma clearances (221 and 185 ml/min), and short terminal half-lives, (30 and 50 min), for the two doses of the drug.",Clinical pharmacokinetics of fazadinium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),min,50,212976,DB01199,Tubocurarine
,6108730,Mean,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],1.42,212977,DB01199,Tubocurarine
,6108730,plasma concentrations at 10,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],1.42,212978,DB01199,Tubocurarine
,6108730,plasma concentrations at 10,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],0.88,212979,DB01199,Tubocurarine
,6108730,50% recovery,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],1.42,212980,DB01199,Tubocurarine
,6108730,50% recovery,"Mean plasma concentrations at 10 and 50% recovery were 1.42 and 0.88 micrograms/ml respectively, demonstrating that the potency of fazadinium is approximately half that of tubocurarine and one eighth that of pancuronium.",Clinical pharmacokinetics of fazadinium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108730/),[μg] / [ml],0.88,212981,DB01199,Tubocurarine
,2936284,elimination half-life,Spontaneous degradation of atracurium in plasma is the major route of elimination in man and contributes to a short elimination half-life (approximatively 20 min).,[Metabolism and pharmacokinetics of atracurium]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2936284/),min,20,233088,DB01199,Tubocurarine
,7604992,effect-site concentration,The effect-site concentration associated with 50% paralysis of twitch increased after 3 weeks from approximately 250 to 750 ng/ml.,The changing pharmacodynamics of metocurine identify the onset and offset of canine gastrocnemius disuse atrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604992/),ng,250,251686,DB01199,Tubocurarine
